LBPH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LBPH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-01), Longboard Pharmaceuticals's share price is $18.84. Longboard Pharmaceuticals's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $8.07. Hence, Longboard Pharmaceuticals's Price to Tangible Book Ratio of today is 2.33.
The historical rank and industry rank for Longboard Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:
During the past 4 years, Longboard Pharmaceuticals's highest Price to Tangible Book Ratio was 3.61. The lowest was 0.64. And the median was 1.31.
A closely related ratio is called PB Ratio. As of today, Longboard Pharmaceuticals's share price is $18.84. Longboard Pharmaceuticals's Book Value per Sharefor the quarter that ended in Mar. 2024 was $8.07. Hence, Longboard Pharmaceuticals's P/B Ratio of today is 2.33.
The historical data trend for Longboard Pharmaceuticals's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Longboard Pharmaceuticals Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Price-to-Tangible-Book | - | 0.81 | 0.91 | 3.61 |
Longboard Pharmaceuticals Quarterly Data | |||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Price-to-Tangible-Book | Get a 7-Day Free Trial | 1.28 | 2.90 | 2.55 | 3.61 | 2.68 |
For the Biotechnology subindustry, Longboard Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Longboard Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Longboard Pharmaceuticals's Price-to-Tangible-Book falls into.
Longboard Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:
Price to Tangible Book | = | Share Price | / | Tangible Book per Share (Q: Mar. 2024 ) |
= | 18.84 | / | 8.069 | |
= | 2.33 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price to Tangible Book | = | Market Cap | / | Tangible Equity | ||||
= | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) |
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Longboard Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Randall Kaye | officer: CMO | 11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121 |
Jane Tiller | director | C/O LONGBOARD PHARMACEUTICALS, INC., 4275 EXECUTIVE DRIVE, SUITE 950, LA JOLLA CA 92037 |
Brandi Roberts | officer: Chief Financial Officer | 12390 EL CAMINO REAL #150, SAN DIEGO CA 92130 |
Phillip M Schneider | director | GEN-PROBE INCORPORATED, 10210 GENETIC CENTER DRIVE, SAN DIEGO CA 92121 |
Vincent Aurentz | director | C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Kevin Robert Lind | director, officer: President and CEO | C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Paul J Sekhri | director | C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588 |
Casey Lynch | director | C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Le Goff Corinne | director | 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139 |
Arena Pharmaceuticals Inc | 10 percent owner | 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Philip Perera | officer: Chief Medical Officer | C/O LONGBOARD PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
From GuruFocus
By Business Wire • 01-08-2024
By Business Wire • 08-30-2023
By Business Wire • 01-04-2024
By Business Wire Business Wire • 02-07-2023
By Business Wire Business Wire • 05-09-2023
By Business Wire • 08-03-2023
By GuruFocus Research • 11-14-2023
By Business Wire Business Wire • 04-11-2023
By Business Wire • 11-01-2023
By Business Wire • 10-05-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.